​
​

PMV Pharmaceuticals (PMVP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

PMVP Stock Forecast

PMV Pharmaceuticals stock forecast is as follows: an average price target of $18.00 (represents a 1046.50% upside from PMVP’s last price of $1.57) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

PMVP Price Target

The average price target for PMV Pharmaceuticals (PMVP) is $18.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $36.00 to $5.00. This represents a potential 1046.50% upside from PMVP's last price of $1.57.

PMVP Analyst Ratings

Buy

According to 4 Wall Street analysts, PMV Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for PMVP stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

PMV Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 08, 2024Jeff JonesOppenheimer$6.00$1.75243.84%282.17%
Apr 11, 2024Kambiz YazdiJefferies$5.00$1.58216.46%218.47%
Nov 17, 2022-H.C. Wainwright$36.00$10.29249.85%2192.99%
Jun 09, 2022-Oppenheimer$33.00$10.24222.27%2001.91%
May 24, 2022-Goldman Sachs$25.00$14.0977.43%1492.36%
Row per page
Go to

The latest PMV Pharmaceuticals stock forecast, released on Nov 08, 2024 by Jeff Jones from Oppenheimer, set a price target of $6.00, which represents a 243.84% increase from the stock price at the time of the forecast ($1.75), and a 282.17% increase from PMVP last price ($1.57).

PMV Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts112
Avg Price Target$6.00$6.00$5.50
Last Closing Price$1.57$1.57$1.57
Upside/Downside282.17%282.17%250.32%

In the current month, the average price target of PMV Pharmaceuticals stock is $6.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 282.17% increase as opposed to PMV Pharmaceuticals's last price of $1.57. This month's average price target is down 0.00% compared to last quarter, and up 9.09% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 08, 2024OppenheimerOutperformOutperformUpgrade
May 13, 2024Craig-Hallum-BuyInitialise
Apr 11, 2024Jefferies-BuyInitialise
Jun 09, 2022OppenheimerOutperformOutperformHold
May 24, 2022Goldman SachsBuyBuyHold
Row per page
Go to

PMV Pharmaceuticals's last stock rating was published by Oppenheimer on Nov 08, 2024. The company gave PMVP a "Outperform" rating, the same as its previous rate.

PMV Pharmaceuticals Financial Forecast

PMV Pharmaceuticals Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

PMV Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PMVP's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

PMV Pharmaceuticals EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict PMVP's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PMV Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

PMV Pharmaceuticals Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-25.27M$-25.01M$-24.50M$-24.50M$-22.56M$-22.18M$-21.25M$-20.32M$-18.49M$-17.83M$-18.02M
High Forecast$-25.27M$-25.01M$-24.50M$-24.50M$-22.56M$-22.18M$-21.25M$-18.80M$-16.95M$-17.83M$-18.02M
Low Forecast$-25.27M$-25.01M$-24.50M$-24.50M$-22.56M$-22.18M$-21.25M$-21.84M$-20.55M$-17.83M$-18.02M
Surprise %-----------

PMV Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PMVP's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

PMV Pharmaceuticals SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

PMV Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PMVP last annual SG&A of $NaN (undefined).

PMV Pharmaceuticals EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.49$-0.48$-0.47$-0.47$-0.44$-0.43$-0.41$-0.39$-0.36$-0.35$-0.35
High Forecast$-0.49$-0.48$-0.47$-0.47$-0.44$-0.43$-0.41$-0.36$-0.33$-0.35$-0.35
Low Forecast$-0.49$-0.48$-0.47$-0.47$-0.44$-0.43$-0.41$-0.42$-0.40$-0.35$-0.35
Surprise %-----------

According to undefined Wall Street analysts, PMV Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PMVP previous annual EPS of $NaN (undefined).

PMV Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PMVPPMV Pharmaceuticals$1.57$18.001046.50%Buy
PEPGPepGen$4.40$29.50570.45%Buy
MOLNMolecular Partners$5.20$29.00457.69%Buy
OPTOpthea$3.28$14.00326.83%Buy
ANEBAnebulo Pharmaceuticals$1.52$6.00294.74%Buy
VIGLVigil Neuroscience$3.05$11.00260.66%Buy
ACRVAcrivon Therapeutics$6.50$21.83235.85%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
MLYSMineralys Therapeutics$12.60$30.00138.10%Buy
PHVSPharvaris$20.50$39.6793.51%Buy
EWTXEdgewise Therapeutics$31.95$45.0040.85%Buy
TRDAEntrada Therapeutics$17.93$20.0011.54%Buy

PMVP Forecast FAQ

Is PMV Pharmaceuticals a good buy?

Yes, according to 4 Wall Street analysts, PMV Pharmaceuticals (PMVP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of PMVP's total ratings.

What is PMVP's price target?

PMV Pharmaceuticals (PMVP) average price target is $18 with a range of $5 to $36, implying a 1046.50% from its last price of $1.57. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will PMV Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for PMVP stock, the company can go up by 1046.50% (from the last price of $1.57 to the average price target of $18), up by 2192.99% based on the highest stock price target, and up by 218.47% based on the lowest stock price target.

Can PMV Pharmaceuticals stock reach $2?

PMVP's average twelve months analyst stock price target of $18 supports the claim that PMV Pharmaceuticals can reach $2 in the near future.

What is PMV Pharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $6 price target for PMV Pharmaceuticals (PMVP) this month, up 282.17% from its last price of $1.57. Compared to the last 3 and 12 months, the average price target increased by 282.17% and increased by 250.32%, respectively.

What are PMV Pharmaceuticals's analysts' financial forecasts?

PMV Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-86.309M (high $-84.785M, low $-87.833M), average SG&A $0 (high $0, low $0), and average EPS is $-1.673 (high $-1.644, low $-1.703). PMVP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-99.28M (high $-99.28M, low $-99.28M), average SG&A $0 (high $0, low $0), and average EPS is $-1.925 (high $-1.925, low $-1.925).